Synergistic effects of anlotinib and DDP on breast cancer: targeting the VEGF/JAK2/STAT3 axis
This study confirms the efficacy of anlotinib or in combination with DDP and elucidates the mechanism behind anlotinib's effectiveness, highlighting its role in inhibiting the JAK2/STAT3 pathway.
Authors
- Chunling Liu (ORCID: https://orcid.org/0000-0002-7498-4511)
- Zhenxian Jia
- Yiming Guan (ORCID: https://orcid.org/0000-0002-5958-4878)
- Hongmei Zhang (ORCID: https://orcid.org/0000-0001-8300-3191)
- Xuemei Zhang (ORCID: https://orcid.org/0000-0003-0705-4231)
- Zheng Wang (ORCID: https://orcid.org/0000-0003-4471-5983)
- Zhi Zhang (ORCID: https://orcid.org/0000-0002-4205-3181)
- Ye Jin
- Tong Cui
Institutions
- Hebei Medical University (CN)
- North China University of Science and Technology (CN)
- Tangshan People's Hospital (CN)
- Tangshan Gongren Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-23
- DOI
- https://doi.org/10.3389/fphar.2024.1494265
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Tangshan Science and Technology Bureau